

1 **Clinical health outcomes of Ebola virus disease survivors eight years post recovery: a cross-**
2 **sectional study in Sierra Leone.**

3
4 Brayden G. Schindell¹, Boghuma K. Titanji², Anne W. Rimoin³, Souradet Y. Shaw⁴, Jia B.
5 Kangbai^{5*}, Jason Kindrachuk^{1*}

6
7 ¹Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine,
8 University of Manitoba, Winnipeg, Canada

9 ²Division of Infectious Disease, Emory University, Atlanta, United States of America

10 ³Department of Epidemiology, Fielding School of Public Health, University of California Los
11 Angeles

12 ⁴Department of Community Health Sciences, Max Rady College of Medicine, University of
13 Manitoba, Winnipeg, Canada

14 ⁵Department of Public Health, Njala University, Sierra Leone

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

30 *Corresponding Author: Jason Kindrachuk (Jason.Kindrachuk@umanitoba.ca); Jia B. Kangbai
31 (JKangbai@tulane.edu)

32 **Abstract**

33 **Background** The West African Ebola virus disease (EVD) epidemic that occurred between 2013-
34 2016 resulted in >28,000 confirmed cases and >11,000 fatalities. Thousands of survivors
35 necessitate an understanding of the long-term health effects and future medical needs of these
36 patients.

37 **Methods** A cross-sectional study of 595 EVD survivors from Sierra Leone and 403 close contacts
38 ($n=998$). An in-person survey conducted between November 2021 and March 2022 included
39 demographics, clinical health symptomology assessment of each organ system and a reproductive
40 health assessment including sexual dysfunction question sets. The frequency of each disorder was
41 examined and the association of each disorder with EVD survival was assessed.

42 **Results** Of 12 number of symptom types, five were reported by >50% of EVD survivors (Ocular,
43 Neurological, Constitutional, Genitourinary, Dermatological), and all but one were reported by
44 >40% of EVD survivors. Symptom types associated with EVD survival included ENT symptoms
45 (AOR: 8.75, 95% CI: 5.63 – 13.60, $p < 0.001$), ocular symptoms (AOR: 7.18, 95% CI: 5.02 –
46 10.25, $p < 0.001$), dermatological symptoms (AOR: 4.16, 95% CI: 3.06 – 5.65, $p < 0.001$) and
47 cardiovascular symptoms (AOR: 2.96, 95% CI: 2.12 – 4.13, $p < 0.001$).

48 **Conclusion** The West Africa EVD epidemic resulted in a high prevalence of persistent health
49 issues among disease survivors. Continued support for survivor services in West Africa is crucial,
50 and future outbreak response planning should include dedicated funding to ensure adequate care
51 for survivors, both during the acute phase of infection and throughout the post recovery period.

52

53

54 **Background**

55 The West African Ebola virus disease (EVD) epidemic of 2013-2016 remains the largest recorded
56 Ebola virus outbreak with 28,652 cases and 11,325 deaths[1]. An estimated 10,000-17,000
57 individuals recovered from EVD during this period, underscoring the need to address both the
58 immediate impacts of EVD outbreaks and the long-term consequences for survivors. [2]. Sierra
59 Leone, which reported the highest number of cases at 14,124 [1, 3]; has 3,466 registered survivors
60 as of 2020, though estimates suggest the total number could be over 5,000.[2]. Understanding the
61 long-term health effects and future medical needs of survivors is crucial[4]. Most published reports
62 on the health of EVD survivors has focused on the first two years post-recovery, with only two
63 studies extending to four years[5, 6] and one study reaching 7 years. [7].

64 The “slow and painful” recovery in survivors was first documented in the Sudan EVD outbreak in
65 1976[8]. More recently the West African EVD epidemic revealed that most EVD survivors
66 experience some measure of persistent health issues[7]. These symptoms and clinical findings
67 manifest as chronic post-infectious syndromes and/or conditions characterized by immune
68 dysfunction[9]. The unprecedented number of survivors has raised questions about long-term
69 health complications of EVD survivorship and the capacity of local health systems to meet these
70 needs[10]. Inconsistent follow-up on the management of sequelae, and limited access to healthcare
71 services have exacerbated the effects of these sequelae[11]. The lack of developed health
72 infrastructure and barriers to accessing care continue to impact the ability of EVD survivors to
73 access the required services that can help improve their overall quality of life[12, 13]. The
74 persistent symptoms experienced by survivors makes it challenging for them to return to their
75 previous lives[14]; for example, most survivors of the Sudan Ebola virus outbreak in the 2000
76 Gulu, Uganda reported an inability to return to work a year after infection[15].

77 A wide range of symptoms has been reported among EVD survivors, affecting multiple body
78 systems. The most commonly reported sequelae in the literature include fatigue, joint pain,
79 headache, muscle pain, abdominal pain, ocular complications, anorexia, memory loss, hearing loss
80 and alopecia[3, 4, 6, 7, 14, 16-25]. However, there is ongoing debate regarding the duration of
81 these sequelae, with some studies indicating symptoms wane over time while others suggest they
82 persist[5].

83 Our study, conducted through a cross-sectional survey, aimed to explore the persistence of
84 sequelae among EVD survivors six to eight years post-survival. We present our findings on the
85 prevalence of sequelae in survivors of the 2013-2016 West African EVD epidemic across Sierra
86 Leone, comparing them to a control group of close contacts from the same regions.

87

88 **Methods**

89 **Study Design**

90 This national cross-sectional study was conducted in Sierra Leone from November 2021 to March
91 2022. It involved simultaneous recruitment and surveying across all affected districts including ;
92 Bo, Bombali, Falaba, Kailahun, Kambia, Karene, Kenema, Koinadugu, Kono, Moyamba, Port
93 Loko, Pujehun, Tonkolili, Western Area Rural, and Western Area Urban [26]. Given that the
94 estimated national population of EVD survivors in Sierra Leone ranges between 3,000 and 5,000,
95 a sample size of 715 participants was determined to provide 95% confidence intervals for our
96 outcome variables, as previously described for this population[26]. To account for potential non-
97 responses and ensure a minimum sample size for analysis, the recruitment target was increased to
98 1,000 participants.

99

100 **Participants**

101 Eligibility criteria: To qualify as an EVD survivor, individuals were required to provide either an
102 EVD discharge card or a certificate from an Ebola treatment unit in Sierra Leone, dated between
103 March 2014 and March 2016, as proof of surviving the West African EVD outbreak. Eligibility
104 for close contacts required them to verify their relationship to an EVD survivor or a deceased EVD
105 patient. This could be established by presenting an EVD discharge card, a certificate, or a death
106 certificate of the deceased EVD patient relative. Finally, all participants needed to be between the
107 ages of 18 and 50 years at the time of recruitment.

108 All participants consented to study participation after being fully informed about its scope,
109 potential outcomes, and their right to withdraw at any time without repercussions. Consent was
110 recorded by participants checking the “yes” box in the consent section at the beginning of the
111 survey.

112 A multistage sampling approach was used, where known survivors provided by the Sierra Leone
113 Association of Ebola Survivors, were stratified by district and gender followed by random
114 sampling within each district, close contacts were identified at the time of recruitment of EVD
115 survivors where survivors were asked if they had any family members interested in participating
116 and had no history of EVD. The multistage sampling started in the South of the country and
117 proceeded counterclockwise ending in the Western region. Due to unreliable internet access in
118 many areas, our recruitment team conducted surveys in person after recruiting participants.
119 Translation to Krio, the most commonly spoken language after English in Sierra Leone was
120 provided, along with assistance to those unable to read.

121

122 **Instruments**

123 Socio-demographics were captured as previously described, and included [26] age, sex assigned
124 at birth, district/province of residence, and body mass index (BMI).

125 Clinical health outcome variables were assessed through symptom screens where participants self-
126 reported symptoms experienced in the past two weeks at the time of the survey. The symptom
127 screen was organized into organ systems, and included chronic medical conditions, infections,
128 ocular symptoms, ear nose and throat (ENT) symptoms, neurological symptoms, constitutional
129 symptoms, cardiovascular symptoms, respiratory symptoms, gastrointestinal symptoms,
130 genitourinary symptoms, musculoskeletal symptoms and dermatology symptoms (a full
131 breakdown can be found in supplemental materials). Participants were asked if they are currently
132 or recently experienced a symptom from a particular organ system and what the frequency of the
133 symptom is, assessed on a 6-point Likert scale from 1 (monthly) to 6 (constantly). Both EVD
134 survivors and close contacts reported symptoms experienced and were also asked whether they
135 had sought medical care and are currently taking medication for symptoms.

136 Both male and female participants were asked questions on sexual health. Female participants were
137 given the female sexual function index (FSFI) which is a 19-item questionnaire that assesses six
138 dimensions of female sexual health: desire, arousal, lubrication, orgasm, satisfaction and pain[27].
139 This questionnaire was designed to measure the multidimensional nature of female sexual health.
140 Items were scored on either a 5-point Likert scale from 1 (Very High) to 5 (Very low/none) or a
141 6-point Likert scale from 0 (No sexual activity) to 5 (Almost always/always) over the last four

142 weeks, with scores ranging from 4 (Severe female sexual dysfunction) to 95 (Normal female sexual
143 function). Female sexual arousal disorder (FSAD) is considered a tentative diagnosis with a score
144 of 57 or less in the FSFI.

145 Male participants were assessed through the international index of erectile dysfunction (IIEF),
146 which is a 15-item questionnaire that assesses five different domains of male sexual health:
147 erectile function, orgasmic function, sexual desire, intercourse satisfaction and overall
148 satisfaction[28]. Items were scored on either a 5-point [1 (Very High) to 5 (Very low/none)] or a
149 6-point Likert scale from 0 (No sexual activity) to 5 (Almost always/always) over the last four
150 weeks, with scores ranging from 6 (Severe male sexual dysfunction) to 75 (Normal male sexual
151 function). screening for male sexual dysfunction is considered when scores are 36 or less on the
152 IIEF and screening for erectile dysfunction is considered with a score of 13 or less on the erectile
153 function question subset.

154

155 **Statistical Analysis**

156 All statistical analyses in this study were conducted using Stata version 17.0 (College Station, TX:
157 StataCorp LLC; 2021). Descriptive statistics included means and standard deviation, medians and
158 interquartile ranges (IQR), and frequency and percentages, where appropriate. To examine the
159 relationships between independent (e.g. demographic, health-related variables) and dependent
160 variables, either the Chi-square test or Fisher's exact test was applied. For univariate, bivariate and
161 multivariate analyses were converted into binary variables based on their respective cut-off scores.
162 In bivariate analysis, variables that demonstrated a p-value of 0.1 or lower (using either Chi-square
163 or Fischer's exact test) were considered for the multivariable logistic regression models. A priori,
164 age, sex assigned at birth, province of residence, and BMI were selected to control for associations
165 between symptomologies and EVD survival status. For the purposes of this study, statistical
166 significance in regression models was defined as a two-tailed p-value of 0.05 or less. Results are
167 presented in the form of adjusted odds ratios (AORs) along with associated 95% confidence
168 intervals (CI).

169

170 **Ethical considerations**

171 Ethical approval for this study was obtained from the University of Manitoba Research Ethics
 172 Board [HS24515 (H2020:538)] and the Office of the Sierra Leone Ethics and Scientific Review
 173 Committee, Government of Sierra Leone.

174

175 **Results**

176 *Participant characteristics*

177 A total of 998 participants comprising 403 close contacts and 595 EVD survivors were included,
 178 with 533 (53.4%) male participants and 465 (46.6%) female participants[26]. Select participant
 179 demographics are described in Table 1; briefly, the average age of participants was not statistically
 180 different ($p = 0.327$) between close contacts (mean = 32.6 years, SD = 8.2 years) and EVD
 181 survivors (mean = 32.1 years, SD = 8.9 years). As far as general health of participants which was
 182 assessed through body mass index (BMI), there was not a significant difference ($p = 0.320$)
 183 between close contacts (mean = 20.8, SD = 12.1) and EVD survivors (mean = 20.2, SD = 8.0).

184

Table 1: Demographic characteristics of participants by close contacts and EVD survivors.

	Close		EVD		Total		p-value
	Contacts		Survivors				
Biological Sex							≤ 0.001
Male	253	62.8%	280	47.1%	533	53.4%	
Female	150	37.2%	315	52.9%	465	46.6%	
Age Group							0.048
<20	25	6.2%	51	8.6%	76	7.6%	
20-24	43	10.7%	81	13.6%	124	12.4%	
25-29	73	18.1%	108	18.2%	181	18.1%	
30-34	97	24.1%	119	20.0%	216	21.6%	
35-39	82	20.3%	86	14.5%	168	16.8%	
40-44	39	9.7%	76	12.8%	115	11.5%	
45+	44	10.9%	74	12.4%	118	11.8%	
BMI							≤ 0.001
Classification							
Underweight	273	70.0%	334	56.8%	607	62.1%	
Normal Weight	78	20.0%	177	30.1%	255	26.1%	
Overweight	10	2.6%	27	4.6%	37	3.8%	
Obese - Class I	1	0.3%	15	2.6%	16	1.6%	
Obese - Class II	1	0.3%	10	1.7%	11	1.1%	
Obese - Class III	27	6.9%	25	4.3%	52	5.3%	
Provinces							≤ 0.001
Northern	13	3.2%	63	10.7%	76	7.7%	

Eastern	153	38.2%	238	40.3%	391	39.4%
Southern	80	20.0%	136	23.0%	216	21.8%
Western	92	22.9%	87	14.7%	179	18.0%
Northwest	63	15.7%	67	11.3%	130	13.1%

185

186 *Main outcomes*

187 EVD survivors were more likely to self-report symptomology across all body systems compared
 188 to close contacts (table 2) when controlled for sex, age group, BMI, and province of residence six-
 189 to-eight years after recovery. The symptom groups with the strongest association at the six-to-
 190 eight-year follow-up (table 3) were ENT symptoms (AOR: 8.75, 95% CI: 5.63 – 13.60, $p < 0.001$),
 191 ocular symptoms (AOR: 7.18, 95% CI: 5.02 – 10.25, $p < 0.001$), dermatological symptoms (AOR:
 192 4.16, 95% CI: 3.06 – 5.65, $p < 0.001$) and cardiovascular symptoms (AOR: 2.96, 95% CI: 2.12 –
 193 4.13, $p < 0.001$).

Table 2: Current Dermatological issues of study population by EVD survival status

	Close Contact		EVD Survivor		p-value
Chronic Medical Conditions	59	14.6%	162	27.2%	≤ 0.001
Infections	254	63.0%	411	69.1%	0.048
Ocular Symptoms	80	19.9%	336	56.5%	≤ 0.001
Ear, Nose and Throat Symptoms	47	11.7%	250	42.0%	≤ 0.001
Neurological Symptoms	235	58.3%	428	71.9%	≤ 0.001
Constitutional Symptoms	253	62.8%	415	69.7%	0.024
Cardiovascular Symptoms	103	25.6%	280	47.1%	≤ 0.001
Respiratory Symptoms	146	36.2%	291	48.9%	≤ 0.001
Gastrointestinal Symptoms	97	24.1%	247	41.5%	≤ 0.001
Genitourinary Symptoms	202	50.1%	374	62.9%	≤ 0.001
Musculoskeletal Symptoms	116	28.8%	257	43.2%	≤ 0.001
Dermatology Symptoms	130	32.3%	366	61.5%	≤ 0.001

194

195

196 **Table 3: Associations with EVD survival by symptom group - Crude and**
 197 **Adjusted Odds Ratios (ORs) and 95% Confidence Intervals (95%CI),**
 198 **Logistic Regression Models**

	Adjusted	
Ocular symptoms		
No	1	[1.00,1.00]
Yes	7.18***	[5.02,10.25]
ENT Symptoms		
No	1	[1.00,1.00]
Yes	8.75***	[5.63,13.60]
Neurological Symptoms		
No	1	[1.00,1.00]
Yes	1.89***	[1.40,2.54]
Constitutional Symptoms		
No	1	[1.00,1.00]
Yes	1.41*	[1.05,1.91]
Cardiovascular Symptoms		
No	1	[1.00,1.00]
Yes	2.96***	[2.12,4.13]
Respiratory Symptoms		
No	1	[1.00,1.00]
Yes	1.63**	[1.21,2.19]
Gastrointestinal Symptoms		
No	1	[1.00,1.00]
Yes	2.15***	[1.54,3.00]
Genitourinary Symptoms		
No	1	[1.00,1.00]
Yes	1.84***	[1.37,2.46]
Musculoskeletal Symptoms		
No	1	[1.00,1.00]
Yes	1.93***	[1.39,2.67]
Dermatological Symptoms		
No	1	[1.00,1.00]
Yes	4.16***	[3.06,5.65]
Observations	973	

199 Exponentiated coefficients; 95% confidence intervals in brackets

200 * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$

201 Adjusted for sex, age, BMI, province of residence.

202

203 *Commonly Reported Symptoms*

204 ENT, Ocular, dermatological and cardiovascular symptoms were more prevalent in EVD survivors

205 compared to close contacts. Frequencies of symptoms by symptom group are reported in Tables

206 A-D of the appendix. Logistic regression adjusting for sex, age group, BMI, and province of
 207 residence was performed on major symptoms reported (Table 4). AORs for ENT symptoms
 208 (frequencies outlined in table A of the appendix) that were highly prevalent among survivors
 209 compared to close contacts were 7.18 for reduced hearing (95% CI: 5.02 – 10.25, $p < 0.001$) and
 210 8.75 for otalgia (95% CI: 5.63 – 13.60, $p < 0.001$). Eye pain (AOR: 1.89, 95% CI: 1.40 – 2.54, p
 211 < 0.001), itchy eyes (AOR: 1.41, 95% CI: 1.05 – 1.91, $p < 0.05$) and eye redness (AOR: 2.96, 95%
 212 CI: 2.12 – 4.13, $p < 0.001$) were prevalent ocular symptomologies (frequencies outlined in table B
 213 of the appendix). The most prevalent dermatological symptoms (frequencies outlined in table C of
 214 the appendix) were itchy skin (AOR: 1.63, 95% CI: 1.21 – 2.19, $p < 0.01$) rash (AOR: 2.15, 95%
 215 CI: 1.54 – 3.00, $p < 0.001$) alopecia (AOR: 1.84, 95% CI: 1.37 – 2.46, $p < 0.001$) and change in
 216 skin colour (AOR: 1.93, 95% CI: 1.39 – 2.67, $p < 0.001$). The most reported cardiovascular
 217 symptoms (frequencies outlined in table D of the appendix) were chest pain (AOR: 5.39, 95% CI:
 218 3.29 – 8.82, $p < 0.001$) and leg pain (AOR: 4.16, 95% CI: 3.06 – 5.65, $p < 0.001$).

219 **Table 4: Associations with EVD survival by symptom – Crude and**
 220 **Adjusted Odds Ratios (AORs) and 95% Confidence Intervals (95%CI),**
 221 **Logistic Regression Models**

	AOR	
Reduced hearing		
No	1	[1.00,1.00]
Yes	7.18***	[5.02,10.25]
Pain in ears		
No	1	[1.00,1.00]
Yes	8.75***	[5.63,13.60]
Eye pain		
No	1	[1.00,1.00]
Yes	1.89***	[1.40,2.54]
Itchy eyes		
No	1	[1.00,1.00]
Yes	1.41*	[1.05,1.91]
Eye redness		
No	1	[1.00,1.00]
Yes	2.96***	[2.12,4.13]
Itchy skin		
No	1	[1.00,1.00]
Yes	1.63**	[1.21,2.19]
Rash		
No	1	[1.00,1.00]
Yes	2.15***	[1.54,3.00]
Alopecia		
No	1	[1.00,1.00]

Yes	1.84***	[1.37,2.46]
Change in skin color		
No	1	[1.00,1.00]
Yes	1.93***	[1.39,2.67]
Chest pain		
No	1	[1.00,1.00]
Yes	5.39***	[3.29,8.82]
Leg pain		
No	1	[1.00,1.00]
Yes	4.16***	[3.06,5.65]
Observations	973	

222 Exponentiated coefficients; 95% confidence intervals in brackets

223 * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$

224 Adjusted for sex, age, BMI, province of residence.

225

226 *Reproductive Health Assessment*

227 Amongst female participants, significantly more EVD survivors (n=56, 19.7%, $p \leq 0.001$)

228 expressed decreased interest in sexual intercourse (table E appendix) than close contacts (n=6,

229 5.0%). The same was not observed for male EVD survivors (n=24, 9.3%, $p \leq 0.086$) and close

230 contacts (n=11, 5.2%). Logistic regression analysis was performed for reproductive health (table

231 5 and 6) under the same conditions as described in earlier sections, stratified by sex at birth. EVD

232 survival was significantly associated with several reproductive health variables, including sexual

233 intercourse (AOR: 5.53, 95% CI: 3.04 – 10.07), decreased interest in sexual intercourse (AOR:

234 3.64, 95% CI: 1.34 – 9.86), irregular periods (AOR: 3.07, 95% CI: 1.75 – 5.36) and no recent

235 pregnancies (AOR: 3.53, 95% CI: 1.69 – 7.34). For males, EVD survivorship was associated with

236 reporting no conceived pregnancies in the last year (AOR: 2.73, 95% CI: 1.29-5.81).

237 **Table 5: Associations Female Reproductive and Sexual Health Associations**

238 **with EVD survival – Crude and Adjusted Odds Ratios (AORs) and 95%**

239 **Confidence Intervals (95%CI), Logistic Regression Models**

	AOR	
Sexual Intercourse in the Last Year		
No	5.53***	[3.04,10.07]
Yes	1	[1.00,1.00]
Decreased Interest in Sexual Intercourse		
No	1	[1.00,1.00]
Yes	3.64*	[1.34,9.86]
Menstruation in the Last Year		

Regular Period	1	[1.00,1.00]
Irregular Period	3.07***	[1.75,5.36]
No Period	1.56	[0.57,4.27]
Pregnant in the Last Year		
No	3.53***	[1.69,7.34]
Yes	1	[1.00,1.00]
Given Birth		
No	1	[1.00,1.00]
Yes	1.28	[0.74,2.20]
Observations	384	

240 Exponentiated coefficients; 95% confidence intervals in brackets

241 * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$

242 Adjusted for sex, age, BMI, province of residence.

243

244 **Table 6: Associations Male Reproductive and Sexual Health Associations**
 245 **with EVD survival – Crude and Adjusted Odds Ratios (AORs) and 95%**
 246 **Confidence Intervals (95%CI), Logistic Regression Models**

AOR		
Sexual Intercourse in the Last Year		
No	1.46	[0.93,2.29]
Yes	1	[1.00,1.00]
Decreased Interest in Sexual Intercourse		
No	1	[1.00,1.00]
Yes	1.75	[0.75,4.10]
Conceived child with partner in the Last Year		
No	2.73**	[1.29,5.81]
Yes	1	[1.00,1.00]
Fathered a child		
No	1	[1.00,1.00]
Yes	1.22	[0.74,2.01]
Observations	463	

247 Exponentiated coefficients; 95% confidence intervals in brackets

248 * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$

249 Adjusted for sex, age, BMI, province of residence.

250

251 Discussion

252 In this study, we present the most prevalent clinical symptoms experienced by EVD survivors
 253 compared to their close contacts, 6-8 years after the West Africa EVD outbreak. Other studies have
 254 reported on persistent ocular manifestations in survivors dating to the Kikwit outbreak, where a
 255 two year follow-up study identified ocular pain, blurry vision and light sensitivity[24]. The same

256 study also identified the presence of highly prevalent symptoms including joint pain, hearing loss
257 and fatigue[24]. These symptoms continue to be among the most reported sequelae in available
258 literature and were among the most reported in this study[3, 4, 6, 7, 14, 16-25]. There are several
259 reports on clinical health outcomes in the immediate aftermath of the West African EVD epidemic,
260 however, there has been a paucity of information on the longer-term clinical health outcomes of
261 EVD survivors.

262 While it has previously been reported that persistence of sequelae diminishes over time, our results
263 suggest that in Sierra Leone this has not been the case[5, 7, 16] (table 2). We report on five
264 symptom types reported by >50% of EVD survivors 6-8 years post recovery, and all but one
265 reported by >40% of EVD survivors[5]. Recent studies including by Wohl et al., the only other
266 published study with long term follow-up of survivors in Liberia included a study population of
267 326 participants who were followed up to five years from Ebola treatment Center (ETC)
268 discharge[7]. It is difficult to compare the findings between two studies in different countries
269 utilizing different survey tools, however some of the differences are notable in results at 5+ years
270 post recovery; including fatigue (12.2% vs 20.2% reported in table I of appendix), headache
271 (20.3% vs 64.4% in table H of appendix), hearing loss (2.8% vs 13.9% in table A of appendix),
272 joint pain (15.8% vs 26.7% in table J of appendix), muscle pain (0.0% vs 5.5% in table J of
273 appendix) and vision impairment (17.4% vs 8.1% in table B of appendix). The experiences
274 reported by survivors of the same epidemic in a similar time frame of assessment demonstrate the
275 variable experiences of long-term sequelae by survivors based on their geographic location and
276 environment. It is challenging to hypothesize on which factors may account for the differences
277 observed in the rates of these various symptomologies (As listed in table 2); however, population
278 sample size, living conditions and health care access are plausible factors that may affect these
279 differences observed. When comparing symptomology to reported rates from another recent study
280 conducted by Bond et al. in Eastern Sierra Leone, with 375 EVD survivors and 1040 close contacts,
281 similar findings of physical symptoms were significantly more commonly reported by survivors
282 compared with close contacts[17]. This study was conducted between 1.6 and 3.3 years after
283 discharge from ETCs suggesting that symptomology rates have remained elevated and stable over
284 the subsequent 3-5 years from the initial recovery period to the 6–8-year follow-up time point
285 reported in our study. Similar findings to those presented here have previously been observed in
286 West Africa regarding reproductive health of female and male EVD survivors. A study conducted

287 from January to April 2016 in Montserrado county, Liberia found that 16.2% of male EVD
288 survivors surveyed reported testicular pain or erectile dysfunction, while 19.7% of female EVD
289 survivors reported having menstrual problems including amenorrhoea and other menstrual
290 irregularities[14]. Another study conducted in February 2015 in Bombali District, Sierra Leone
291 found that 2.2% of female EVD survivors reported a menstrual disorder and 3.4% of male EVD
292 survivors reported erectile dysfunction[29]. A study conducted in Liberia between 2016 and 2017
293 including 111 female participants from Monrovia, reported 25.7% of female participants had
294 irregular menstruation of unknown cause[30]. The same group reported in a qualitative study
295 including 69 women, that 50% of female survivors from Liberia had reported decreased sexual
296 libido following recovery with several women also reporting pain during intercourse, and 46% of
297 participants reporting some of menstrual irregularity[31]. We made similar observations in our
298 study (table 6 and tables E and F of the appendix,) with female survivors also reporting menstrual
299 changes and changes in sexual libido. Reproductive health changes experienced by EVD survivors
300 remain understudied. Additionally, there are long-term social and mental health effects, as we have
301 previously reported in this cohort[26, 32]. Many survivors experience social isolation, with their
302 relationship status being directly associated with stigmatization. The mental health effects are also
303 profound, with 45.7% of EVD survivors reporting post-traumatic stress disorder related to their
304 Ebola experience and its impact on their interpersonal relationships[26, 32]. There is a lack of data
305 on the factors related to the host and the disease that predict symptoms and the mechanisms behind
306 their persistence. Understanding the viral and immune-related mediators may help develop
307 targeted treatment plans to address these chronic symptoms for EVD survivors[24, 33].

308 Investigations into the mechanisms that explain the sequelae reported by EVD survivors have been
309 limited. However, some studies have found associations with various symptoms[24, 33]. A 23-
310 month follow-up study identified increased blood markers of inflammation, intestinal tissue
311 damage, T-cell and B-cell activation and a depletion of circulating dendritic cells[9]. Additionally
312 the level of adaptive immune cells remained highly elevated two years after recovery in EVD
313 survivors tested[9]. The study also found that immune cell phenotypes shifted towards activated
314 cytotoxic T cells, exhausted B cells, proinflammatory monocytes and non-classical NK cells,
315 which are common in chronic viral infections. Elevated levels of inflammatory markers and
316 activation of antiviral pathways have been reported to persist in the absence of detectable virus[9].
317 Specifically D dimer, IFN- γ , IL-8 and TNF-alpha were shown to persist. Markers of chronic

318 immune activation such as CCL5 and sCD40L, and markers of potential liver and kidney damage,
319 including higher levels of alanine transaminase, aspartate transaminase, bilirubin, creatine and
320 creatine kinase, were also found to persist[6, 9, 34]. These findings demonstrate that the chronic
321 effects of EVD infection continue to manifest in physical symptoms that severely impact the day-
322 to-day lives of EVD survivors across all organ systems.

323 Symptoms have made it difficult to get back to their prior lives they lived[14]. Among the most
324 reported symptoms in this study were dermatological issues, including itchy skin, rashes, alopecia,
325 and hyperpigmentation. While these symptoms have been previously reported, there are no recent
326 reports discussing them in detail[3, 14]. Given their high visibility and prevalence (61.5% in this
327 cohort and previously reported at 48.8%), these symptoms can be highly discriminating and visible
328 sequelae among survivors[14]. Previous reports suggest reintegration into the community was
329 limited[20], with many survivors reporting a lower socioeconomic status than prior to EVD (90%),
330 less favourable work (79%) and worse psychological status (60%)[20]. In Kikwit, Democratic
331 Republic of the Congo 70% of survivors indicated capacity to work was worse 21 months
332 following infection compared to before suggesting that the physical sequelae, as observed in this
333 study affects their ability to return to their prior lives[24]. 60.9% of women seeking care at the
334 survivor clinic in Kenema were female[22]. Some survivors may benefit from rheumatologic,
335 musculoskeletal, or neurologic evaluation in the recovery phase[11].

336 A limitation of this study is the reliance on self-reporting symptomologies without formal
337 assessment of impairments through physical examinations. This was mitigated by using validated
338 standardized questionnaires with objective measurements of symptoms and direct comparisons to
339 a control population. The study's cross-sectional design limited our ability to establish cause-and-
340 effect relationships or analyse change over time meaningfully. Recruiting close contacts as a
341 control population allowed us to match the economic, geographic and social experiences between
342 the two study groups as much as possible. Exploratory analyses conducted may have increased the
343 risk of type I error in this study. It is possible that individuals with more severe symptoms were
344 more likely to participate, but this was mitigated through broad recruitment both in terms of the
345 number of survivors and their geographic distribution.

346

347 **Conclusions**

348 Our results indicate that many, if not most, EVD survivors from the West Africa EVD epidemic
349 continue to experience persistent health issues. Factors such as inconsistent follow up on the
350 management of sequelae[11], limited access to healthcare services difficulty in obtaining
351 necessary mediations or follow up care, poor health seeking behavior, and inadequate access to
352 quality healthcare have compounded the challenges in managing these symptoms.[35]
353 Additionally, the withdrawal of support without a proper transition period has led to issues like
354 food insecurity, further exacerbating the long-term sequelae observed in our study.

355 Given the chronic nature of EVD- associated sequelae, it is crucial to consider funding and
356 strengthening existing medical infrastructure in affected countries to ensure long-term follow up
357 and care.[25]. Sustained support for survivor services in West Africa is essential, and funding for
358 survivor follow-up should be integrated into future outbreak response planning provide
359 to provide adequate care both during acute infection and throughout the post-recovery period[25].

360

361 **Contributors**

362 JK and JBK conceived the study, while BGS, JBK, SYS, and JK designed the study. JBK lead the
363 recruitment and in-country support in Sierra Leone. BGS BKT SYS analysed the data. BGS
364 prepared the manuscript. JK supervised the study, analysis and writing process. All authors
365 contributed to the intellectual content of the manuscript and read and approved the final version of
366 the manuscript.

367

368 **Declaration of Interest**

369 The authors declare no competing interests.

370

371 **Data Sharing**

372 Due to the sensitive nature of our survey and the involvement of human participants we did not
373 receive approval to collect raw participant identified data from The University of Manitoba
374 Research Ethics Board or the Sierra Leone Ethics and Scientific Review Committee. While
375 participants additionally consented to the study with the knowledge that their data was collected
376 in an anonymized manner with the only record of participants being record of payment only
377 accessible by JK and JBK and securely stored in an encrypted file. Upon reasonable request
378 however, the anonymized raw study data can be made available through the following persons; 1)

379 from UM REB by contacting the office (Email: bannreb@umanitoba.ca) 2) Edward Foday,
380 Research and Publications Specialist, Sierra Leone Ethics and Scientific Review Committee,
381 Directorate of Policy, Planning and Information, Ministry of Health and Sanitation, Fifth Floor,
382 Youyi Building, East Wing, Freetown, Sierra Leone (Email: efoday@health.gov.sl).

383

384 **Acknowledgements**

385 We would like to thank our funding sources JK is funded by a Tier 2 Canada Research Chair in
386 the Molecular Pathogenesis of Emerging and Re-Emerging Viruses provided by the Canadian
387 Institutes of Health Research (Grant no. 950-231498), and the Canadian Institutes of Health
388 Research (Grant no. PJT-175098). BKT has received funding support from NIH Building
389 Interdisciplinary Careers in Women's Health (BIRCWH) Grant (K12HD085850) and from
390 Emory's Center AIDS Research Grant (P30 AI050409). We would like to thank both the EVD
391 survivor and close contact participants of this study. We would also like to thank the participant
392 recruiters for their work and support. We would also like to thank the Sierra Leone Ebola Survivors
393 Association.

394

395 **Abbreviations**

396 EVD (Ebola virus disease); BMI (body mass index); ENT (ear, nose and throat); FSFI (Female
397 sexual function index); FSAD (Female sexual arousal disorder); IIEF (International index of
398 erectile function); IQR (Interquartile range); AOR (Adjusted odds ratio); CI (Confidence
399 interval); ETC (Ebola treatment Centre)

400

401 **References**

- 402 1. Centers for Disease Control and Prevention. History of Ebola Virus Disease (EVD)
403 Outbreaks 2024 [December July 21, 2024]. Available from:
404 <https://www.cdc.gov/vhf/ebola/history/chronology.html#print>.
- 405 2. Alva S, Davis N, Stan L, Pivato I, Sanderson J. Conducting mixed-methods research with
406 Ebola survivors in a complex setting in Sierra Leone. BMC Public Health. 2020;20(1):1346. Epub
407 2020/09/05. doi: 10.1186/s12889-020-09469-9. PubMed PMID: 32883281; PubMed Central
408 PMCID: PMC7470604.
- 409 3. Tiffany A, Vetter P, Mattia J, Dayder J-A, Bartsch M, Kasztura M, et al. Ebola virus disease
410 complications as experienced by survivors in Sierra Leone. Clin Infect Dis. 2016;62(11):1360-6.
411 doi: 10.1093/cid/ciw158.

- 412 4. Clark DV, Kibuuka H, Millard M, Wakabi S, Lukwago L, Taylor A, et al. Long-term
413 sequelae after Ebola virus disease in Bundibugyo, Uganda: a retrospective cohort study. *Lancet*
414 *Infect Dis.* 2015;15(8):905-12. Epub 2015/04/26. doi: 10.1016/S1473-3099(15)70152-0.
415 PubMed PMID: 25910637.
- 416 5. Diallo MSK, Toure A, Sow MS, Kpamou C, Keita AK, Taverne B, et al. Understanding long-
417 term evolution and predictors of sequelae of Ebola virus disease survivors in Guinea: a 48-
418 month prospective, longitudinal cohort study (PostEboGui). *Clin Infect Dis.* 2021;73(12):2166-
419 74. doi: 10.1093/cid/ciab168.
- 420 6. Tozay S, Fischer WA, Wohl DA, Kilpatrick K, Zou F, Reeves E, et al. Long-term
421 complications of Ebola virus disease: prevalence and predictors of major symptoms and the role
422 of inflammation. *Clin Infect Dis.* 2020;71(7):1749-55. doi: 10.1093/cid/ciz1062.
- 423 7. Wohl DA, Fischer WA, Mei W, Zou F, Tozay S, Reeves E, et al. Post-Ebola Symptoms 7
424 Years after Infection: The natural history of Long Ebola. *Clin Infect Dis.* 2022. Epub 2022/09/07.
425 doi: 10.1093/cid/ciac732. PubMed PMID: 36065768.
- 426 8. World Health Organization. Ebola haemorrhagic fever in Sudan, 1976. Report of a
427 WHO/International Study Team. *Bull World Health Organ.* 1978;56:247-70.
- 428 9. Wiedemann A, Foucat E, Hocini H, Lefebvre C, Hejblum BP, Durand M, et al. Long-lasting
429 severe immune dysfunction in Ebola virus disease survivors. *Nat Commun.* 2020;11:3730. doi:
430 10.1038/s41467-020-17489-7.
- 431 10. Secor A, Macauley R, Stan L, Kagone M, Sidikiba S, Sow S, et al. Mental health among
432 Ebola survivors in Liberia, Sierra Leone and Guinea: results from a cross-sectional study. *BMJ*
433 *Open.* 2020;10(5):e035217. Epub 2020/05/29. doi: 10.1136/bmjopen-2019-035217. PubMed
434 PMID: 32461296; PubMed Central PMCID: PMC67259862.
- 435 11. Djomealeu ML, Rogers AB, Barrie MB, Rutherford GW, Weiser SD, Kelly JD. Long-term
436 consequences of food insecurity among Ebola virus disease-affected households after the 2013-
437 2016 epidemic in rural communities of Kono District, Sierra Leone: a qualitative study. *PLOS*
438 *Glob Public Health.* 2022;2(10):e0000770. doi: 10.1371/journal.pgph.0000770.
- 439 12. World Health Organization. Mental health atlas: 2011: World Health Organization; 2011.
- 440 13. Mahase E. Sierra Leone: Ebola and war survivors failed by lack of mental health services,
441 Amnesty finds. *BMJ.* 2021;373:n1381. Epub 2021/05/29. doi: 10.1136/bmj.n1381. PubMed
442 PMID: 34045237.
- 443 14. Wilson HW, Amo-Addae M, Kenu E, Ilesanmi OS, Ameme DK, Sackey SO. Post-Ebola
444 Syndrome among Ebola Virus Disease Survivors in Montserrado County, Liberia 2016. *Biomed*
445 *Res Int.* 2018;2018:1909410. Epub 2018/07/28. doi: 10.1155/2018/1909410. PubMed PMID:
446 30050920; PubMed Central PMCID: PMC6046154.
- 447 15. Wendo C. Caring for the survivors of Uganda's Ebola epidemic one year on. *Lancet.*
448 2001;358(9290):1350. doi: 10.1016/S0140-6736(01)06467-4.
- 449 16. Group PIS, Sneller MC, Reilly C, Badio M, Bishop RJ, Eghrari AO, et al. A Longitudinal
450 Study of Ebola Sequelae in Liberia. *N Engl J Med.* 2019;380(10):924-34. Epub 2019/03/12. doi:
451 10.1056/NEJMoa1805435. PubMed PMID: 30855742; PubMed Central PMCID:
452 PMC6478393.
- 453 17. Bond NG, Grant DS, Himmelfarb ST, Engel EJ, Al-Hasan F, Gbakie M, et al. Post-Ebola
454 Syndrome Presents With Multiple Overlapping Symptom Clusters: Evidence From an Ongoing
455 Cohort Study in Eastern Sierra Leone. *Clin Infect Dis.* 2021;73(6):1046-54. Epub 2021/04/07.

- 456 doi: 10.1093/cid/ciab267. PubMed PMID: 33822010; PubMed Central PMCID:
457 PMCPMC8442780.
- 458 18. Mudalegundi S, Ross RD, Larbelee J, Amegashie F, Dolo RF, Prakalapakorn GS, et al.
459 Long-term decrease in intraocular pressure in survivors of Ebola virus disease in the partnership
460 for research on vaccines and infectious diseases in Liberia (PREVAIL) III study. *Ophthalmol Sci*.
461 2023;3(2):100238. doi: 10.1016/j.xops.2022.100238.
- 462 19. Chertow DS. Understanding long-term effects of Ebola virus Disease. *Nat Medicine*.
463 2019;25:711-5. doi: 10.1038/s41591-019-0444-0.
- 464 20. Delamou A, Camara BS, Kolie JP, Guemou AD, Haba NY, Marquez S, et al. Profile and
465 reintegration experience of Ebola survivors in Guinea: a cross-sectional study. *Trop Med Int*
466 *Health*. 2017;22(3):254-60. Epub 2016/12/10. doi: 10.1111/tmi.12825. PubMed PMID:
467 27935657.
- 468 21. Epstein L, Wong KK, Kallen AJ, Uyeki TM. Post-Ebola signs and symptoms in U.S.
469 survivors. *New England Journal of Medicine*. 2015;373(25):2484-6. doi:
470 10.1056/NEJMc1506576.
- 471 22. Mohammed H, Vandy AO, Stretch R, Otieno D, Prajapati M, Calderon M, et al. Sequelae
472 and Other Conditions in Ebola Virus Disease Survivors, Sierra Leone, 2015. *Emerg Infect Dis*.
473 2017;23(1):66-73. Epub 2016/12/17. doi: 10.3201/eid2301.160631. PubMed PMID: 27983503;
474 PubMed Central PMCID: PMCPMC5176247.
- 475 23. Nanyonga M, Saidu J, Ramsay A, Shindo N, Bausch DG. Sequelae of Ebola Virus Disease,
476 Kenema District, Sierra Leone. *Clin Infect Dis*. 2016;62(1):125-6. Epub 2015/09/10. doi:
477 10.1093/cid/civ795. PubMed PMID: 26349549.
- 478 24. Rowe AK, Bertolli J, Khan AS, Mukunu R, Muyembe-Tamfum JJ, Bressler D, et al. Clinical,
479 virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their
480 household contacts, in Kikwit, Democratic Republic of the Congo. *J Infect Dis*. 1999;179:S28-35.
- 481 25. de St Maurice A, Ervin E, Orone R, Choi M, Dokubo EK, Rollin PE, et al. Care of Ebola
482 Survivors and Factors Associated With Clinical Sequelae—Monrovia, Liberia. *Open Forum Infect*
483 *Dis*. 2018;5(10):ofy239. Epub 2018/11/06. doi: 10.1093/ofid/ofy239. PubMed PMID: 30386807;
484 PubMed Central PMCID: PMCPMC6202424.
- 485 26. Schindell BG, Kangbai JB, Shaw SY, Kindrachuk J. Stigmatization of Ebola virus disease
486 survivors in 2022, a cross-sectional study of survivors in Sierra Leone. *J Infect Public Health*.
487 2023. doi: 10.1016/j.jiph.2023.10.025.
- 488 27. Rosen R, Brown C, Heiman J, Leiblum S, Meston C, Shabsigh R, et al. The Female Sexual
489 Function Index (FSFI): A multidimensional self-report instrument for the assessment of Female
490 Sexual Function. *J Sex Marital Ther*. 2000;26:191-208.
- 491 28. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international
492 index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction.
493 *Urology*. 1997;49(6):822-30. doi: 10.1016/s0090-4295(97)00238-0.
- 494 29. Nabena EP, Bakare WA, Ilesanmi OS, Anyanwu R, Akuechiama JC, Inyang SEJ, et al.
495 Health problems of Ebola virus disease survivors in Sierra Leone, 2015: making a case for
496 follow-up care after discharge from Ebola treatment centres. *Open Med J*. 2015;2:53-8. doi:
497 10.2174/1874220301401010053.
- 498 30. Godwin CL, Wohl DA, Fischer Nd WA, Singh K, Hawks DA, Devore EE, et al. Reproductive
499 health sequelae among women who survived Ebola virus disease in Liberia. *Int J Gynaecol*

- 500 Obstet. 2019;146(2):212-7. Epub 2019/05/11. doi: 10.1002/ijgo.12858. PubMed PMID:
501 31074837; PubMed Central PMCID: PMC6675397.
- 502 31. Godwin CL, Buller A, Bentley M, Singh K. Understanding the personal relationships and
503 reproductive health changes of female survivors of Ebola infection in Liberia. In: Schwartz DA,
504 Anoko JN, Abramowitz SA, editors. Pregnant in the time of Ebola: women and their children in
505 the 2013-2015 West African epidemic. Cham, Switzerland: Springer; 2019. p. 103-20.
- 506 32. Schindell BG, Fredborg B, Kowalec K, Shaw SY, Kangbai JB, Kindrachuk J. The state of
507 mental health among Ebola virus disease survivors through a cross-sectional study in Sierra
508 Leone. *BMJ Glob Health*. 2024;9:e015098. doi: 10.1136/bmjgh-2024-015098.
- 509 33. Mattia JG, Vandy MJ, Chang JC, Platt DE, Dierberg K, Bauch DG, et al. Early clinical
510 sequelae of Ebola virus disease in Sierra Leone: a cross-sectional study. *Lancet Infect Dis*.
511 2016;16:331-38. doi: 10.1016/S1473-3099(15)00489-2.
- 512 34. Wadoum REG, Sevalie S, Kargbo MB, Clarke A, Bangura S, Kargbo M, et al. Identification
513 of laboratory biomarkers for early detection and clinical management of post-acute syndrome
514 among survivors of the 2013-2016 West Africa Ebola Outbreak in Sierra Leone. *J Blood Med*.
515 2023;11(14):119-32. doi: 10.2147/JBM.S371239.
- 516 35. Jagadesh S, Sevalie S, Fatoma R, Sesay F, Sahr F, Faragher B, et al. Disability Among
517 Ebola Survivors and Their Close Contacts in Sierra Leone: A Retrospective Case-Controlled
518 Cohort Study. *Clin Infect Dis*. 2018;66(1):131-3. Epub 2017/10/12. doi: 10.1093/cid/cix705.
519 PubMed PMID: 29020205; PubMed Central PMCID: PMC6675397.
- 520